嵌合抗原受体（CAR）疗法已成为癌症治疗领域的突破性进展，它利用工程化人体免疫细胞的力量来靶向并消除癌细胞。近年来，人们对 CAR 疗法的兴趣和投资不断增加，突显了其在临床研究中的深远意义，使其成为个性化癌症治疗领域快速扩展的前沿领域。 CAR 疗法设计的关键一步是选择正确的靶点，因为它决定了疗法针对癌细胞的有效性、安全性和特异性，同时不伤害健康组织。在此，我们提出了一套工具，用于利用癌症基因组图谱和基因型组织表达项目的表达数据来识别和分析潜在的 CAR 靶标，这些工具在 CARTAR 网站上实施。这些工具专注于精确定位肿瘤相关抗原，确保靶点选择性并评估特异性以避免肿瘤外毒性，并可用于合理设计双CAR。此外，可以使用癌细胞系百科全书的表达数据来探索癌细胞系中的候选靶标表达。据我们所知，CARTAR 是第一个致力于系统搜索 CAR 治疗合适候选靶点的网站。 CARTAR 可通过 https://gmxenomica.github.io/CARTAR/ 公开访问。© 作者 2024。由牛津大学出版社出版。

Chimeric antigen receptor (CAR) therapy has emerged as a ground-breaking advancement in cancer treatment, harnessing the power of engineered human immune cells to target and eliminate cancer cells. The escalating interest and investment in CAR therapy in recent years emphasize its profound significance in clinical research, positioning it as a rapidly expanding frontier in the field of personalized cancer therapies. A crucial step in CAR therapy design is choosing the right target as it determines the therapy's effectiveness, safety and specificity against cancer cells, while sparing healthy tissues. Herein, we propose a suite of tools for the identification and analysis of potential CAR targets leveraging expression data from The Cancer Genome Atlas and Genotype-Tissue Expression Project, which are implemented in CARTAR website. These tools focus on pinpointing tumor-associated antigens, ensuring target selectivity and assessing specificity to avoid off-tumor toxicities and can be used to rationally designing dual CARs. In addition, candidate target expression can be explored in cancer cell lines using the expression data for the Cancer Cell Line Encyclopedia. To our best knowledge, CARTAR is the first website dedicated to the systematic search of suitable candidate targets for CAR therapy. CARTAR is publicly accessible at https://gmxenomica.github.io/CARTAR/.© The Author(s) 2024. Published by Oxford University Press.